Effects of Secukinumab on Synovitis and Enthesitis in Patients with Psoriatic Arthritis: 52-week Clinical and Ultrasound Results from the Randomised, Double-blind ULTIMATE Trial with Open Label Extension

Semin Arthritis Rheum 2023;63:152259

This Phase 3 RCT by D’Agostino, et al. assessed the long-term effect of secukinumab to placebo at tissue level on synovitis and enthesitis, and across all PsA manifestations. They found consistent improvements in clinically and ultrasound-assessed synovitis and enthesitis.

The ULTIMATE study randomised patients with PsA to secukinumab 150 mg or 300 mg, or to placebo over 52 weeks. The placebo group was switched to secukinumab at Week 12. There was then an optional open-label period from Week 24 to 52.